Statin use and survival in 16,098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era
British Journal of Haematology — Brånvall E, Ekberg S, Eloranta S, et al. | August 03, 2021
In patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL), improved lymphoma survival was not achieved with statin use, however, statins seemed safe to use during lymphoma treatment.
A total 16,098 incident NHL/CLL patients in Sweden from 2007 to 2013 were included.
Cox regression was applied.
Statin use at diagnosis was reported by 20% of patients.
Seemingly, there was no increase in lymphoma-specific mortality in relation to statin use, for actively treated patients with follicular lymphoma.
In CLL cases, an association of statin use with all-cause and cardiovascular mortality was evident but there was absence of a consistent link with lymphoma-specific mortality.
Using statins during rituximab treatment seemed a safe treatment strategy.